Atara Biotherapeutics
ATRA
112 hedge funds and large institutions have $833M invested in Atara Biotherapeutics in 2019 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 60 increasing their positions, 15 reducing their positions, and 26 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 15
128% more call options, than puts
Call options by funds: $2.84M | Put options by funds: $1.25M
0.05% more ownership
Funds ownership: 4.34% → 4.39% (+0.05%)
3% less funds holding
Funds holding: 116 → 112 (-4)
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
18% less capital invested
Capital invested by funds: $1.01B → $833M (-$179M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$42.9M |
| 2 |
BG
Baupost Group
Boston,
Massachusetts
|
+$19.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$17.9M |
| 4 |
Morgan Stanley
New York
|
+$14.3M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$14.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$44.8M |
| 2 |
Neuberger Berman Group
New York
|
-$5.79M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.33M |
| 4 |
Millennium Management
New York
|
-$3.91M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.32M |
ATRA Hedge Fund Activity: Q3 2019 in Review
112 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2019, worth a combined $833M — down 18% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ATRA and 22 opened new positions — a net loss of 4 holders — while 15 trimmed existing stakes and 60 added.
The largest buyer was Maverick Capital, adding an estimated $42.9M. The largest seller was Fidelity Investments, cutting an estimated $44.8M.
- 112 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2019, down from 116 in Q2 2019.
- Funds reported $833M of Atara Biotherapeutics stock for Q3 2019, down 18% quarter-over-quarter.
- 22 funds opened new Atara Biotherapeutics positions in Q3 2019 and 26 closed out, a net change of -4 holders.
- The largest Atara Biotherapeutics buyer in Q3 2019 was Maverick Capital, an estimated $42.9M added.
- The largest Atara Biotherapeutics seller in Q3 2019 was Fidelity Investments, an estimated $44.8M sold.
Based on aggregated 13F filings for Q3 2019.